LIQUIDIA CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
LIQUIDIA CORPORATION (LQDA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 10.12 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-03-05
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 5.43K shares, a 86.65% decline year-over-year.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2024-12-31 was 12.41K shares, a 30168.29% increase year-over-year.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2024-09-30 was 40.67K shares, a 713.32% increase year-over-year.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 10.12K shares.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 150.59K shares, a 89.65% decline from fiscal 2022.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 1.46M shares, a 31.94% increase from fiscal 2021.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2021 was 1.10M shares, a 46.97% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 5.43K shares derived: sum of 2 quarters · filed 2026-03-05 | 10.12K shares 10-K · filed 2026-03-05 | |
| 2025-09-30 | 5.43K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | 10.12K shares 10-Q · filed 2025-11-03 | ||
| 2025-06-30 | 4.69K shares 10-Q · filed 2025-08-12 | |||
| 2024-12-31 | 12.41K shares derived: 8-K 12 month − 10-Q 9 month · filed 2025-05-08 | 53.08K shares derived: sum of 2 quarters · filed 2025-05-08 | 189.34K shares derived: sum of 3 quarters · filed 2025-05-08 | 192.34K shares 8-K · filed 2025-05-08 |
| 2024-09-30 | 40.67K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 176.93K shares derived: sum of 2 quarters · filed 2024-11-13 | 179.93K shares 10-Q · filed 2024-11-13 | 179.97K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 136.26K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 139.26K shares 10-Q · filed 2024-08-07 | 139.30K shares derived: sum of 3 quarters · filed 2024-08-07 | 144.30K shares derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | 3.00K shares 10-Q · filed 2024-05-13 | 3.04K shares derived: sum of 2 quarters · filed 2024-05-13 | 8.04K shares derived: sum of 3 quarters · filed 2024-05-13 | 147.47K shares derived: sum of 4 quarters · filed 2024-05-13 |
| 2023-12-31 | 41.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | 5.04K shares derived: sum of 2 quarters · filed 2024-03-13 | 144.47K shares derived: sum of 3 quarters · filed 2024-03-13 | 150.59K shares 10-K · filed 2024-03-13 |
| 2023-09-30 | 5.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 144.43K shares derived: sum of 2 quarters · filed 2023-11-07 | 150.55K shares 10-Q · filed 2023-11-07 | 192.48K shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 139.43K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 145.55K shares 10-Q · filed 2023-08-10 | 187.48K shares derived: sum of 3 quarters · filed 2023-08-10 | 397.31K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 6.12K shares 10-Q · filed 2023-05-08 | 48.05K shares derived: sum of 2 quarters · filed 2023-05-08 | 257.87K shares derived: sum of 3 quarters · filed 2023-05-08 | 519.30K shares derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | 41.93K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | 251.75K shares derived: sum of 2 quarters · filed 2023-03-20 | 513.18K shares derived: sum of 3 quarters · filed 2023-03-20 | 1.46M shares 10-K · filed 2023-03-20 |
| 2022-09-30 | 209.82K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 471.25K shares derived: sum of 2 quarters · filed 2022-11-08 | 1.41M shares 10-Q · filed 2022-11-08 | 1.45M shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 261.43K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 1.20M shares 10-Q · filed 2022-08-11 | 1.25M shares derived: sum of 3 quarters · filed 2022-08-11 | 1.34M shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 942.49K shares 10-Q · filed 2022-05-12 | 983.68K shares derived: sum of 2 quarters · filed 2022-05-12 | 1.08M shares derived: sum of 3 quarters · filed 2022-05-12 | 1.23M shares derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | 41.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 134.03K shares derived: sum of 2 quarters · filed 2022-03-17 | 291.68K shares derived: sum of 3 quarters · filed 2022-03-17 | 1.10M shares 10-K · filed 2022-03-17 |
| 2021-09-30 | 92.84K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | 250.48K shares derived: sum of 2 quarters · filed 2021-11-03 | 1.06M shares 10-Q · filed 2021-11-03 | |
| 2021-06-30 | 157.64K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | 969.22K shares 10-Q · filed 2021-08-10 | ||
| 2021-03-31 | 811.58K shares 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | 750.68K shares 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |